SNPMiner Trials by Shray Alag


SNPMiner Trials: Clinical Trial Report


Report for Clinical Trial NCT04006340

Developed by Shray Alag, 2019.
SNP Clinical Trial Gene

Comparison of Empirical and Genotypic Resistance Guided Tailored Therapy for Helicobacter Pylori Infection

We aimed to compare the efficacy of genotypic resistance-guided tailored therapy vs empirical therapy for eradication of Helicobacter pylori (H. pylori) infection in randomized controlled trials.

NCT04006340 Helicobacter Pylori 23S rRNA Clarithromycin Resistance Mutation Helicobacter Pylori Infection
MeSH: Infection Communicable Diseases Helicobacter Infections

3 Interventions

Name: triple therapy

Description: esomeprazole 40 mg, amoxicillin 1 g, clarithromycin 500 mg twice a day for 10 days

Type: Combination Product

Empirical group Genotypic resistance-guided tailored group

Name: quadruple therapy

Description: esomeprazole 40 mg and bismuth 300mg twice daily, tetracycline 500 mg four times daily, metronidazole 500mg three times daily for 10 days

Type: Combination Product

Genotypic resistance-guided tailored group

Name: dual-priming oligonucleotide-based multiplex (DPO)-PCR test

Description: Resistance of clarithromycin 23S rRNA point mutation

Type: Diagnostic Test

Genotypic resistance-guided tailored group


Primary Outcomes

Description: Eradication rate of H. pylori infection

Measure: Eradication rate

Time: 13C-UBT at least 4 weeks after completion of treatment

Purpose: Treatment

Allocation: Randomized

Parallel Assignment


There are 2 SNPs

SNPs


1 A2142G

This is a method to confirm the mutation of A2142G and A2143G by PCR, which are known to be highly related to the resistance of clarithromycin 23S rRNA point mutation. --- A2142G ---


2 A2143G

This is a method to confirm the mutation of A2142G and A2143G by PCR, which are known to be highly related to the resistance of clarithromycin 23S rRNA point mutation. --- A2142G --- --- A2143G ---



HPO Nodes